CARDINAL HEALTH INC News
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
see moreCARDINAL HEALTH INC Market News
6d
Cardinal Health Soars: Q2 Beat Fuels Buybacks Now!
- Cardinal Health (CAH) surged after a strong Q2 FY2026 report that lifted guidance and continued aggressive share repurchases. Investor optimism—highlighted by a Weiss Ratings uptick—remains the short-term catalyst, while execution in specialty services and reimbursement uncertainty are primary risks. No new, material developments emerged in the most recent week.
20d
Cardinal Health Order Express Fuels Specialty Push
Cardinal Health (CAH) bolstered its specialty and logistics positioning this week with the rollout of the Order Express high-speed logistics platform and the finalized acquisition of Specialty Networks. These concrete moves — plus renewed competitive dynamics after OptumRx contract shifts — point to revenue diversification, margin pressure alleviation, and measurable operational improvements investors should track.
27d
Cardinal Health Climbs Near 52-Week High CAH Rally
Cardinal Health (CAH) gained 2.17% on Feb 17, 2026, closing at $225.58 and trading just below its 52-week high of $230.81. The move outpaced healthcare peers amid a modest S&P 500 uptick; trading volume was slightly below the 50-day average. No other major sector-specific headlines emerged in the past week, leaving technical momentum and upcoming catalysts as primary drivers for investors.
16 Feb at 04:12
Cardinal Health Ups FY26 EPS Outlook to $10+
Cardinal Health raised its FY2026 non‑GAAP EPS guidance to at least $10, citing strong Specialty and BioPharma growth, broad ContinuCare rollout, and successful contract transitions ahead of Medicare drug‑pricing changes—key developments that materially affect CAH shares.
09 Feb at 04:12
Cardinal Health Surges: Q2 Beat, Guidance Raised!!
Cardinal Health (CAH) reported a strong Q2 FY2026 with a revenue beat, raised full-year EPS guidance, and signaled continued growth from higher-margin specialty services (Sonexus, BioPharma). Technical strength (RS Rating 91) and aggressive capital returns contrast with elevated debt and $4.3B opioid liabilities.